promestriene
Promestriene, also known as estradiol 3-propyl 17β-methyl diether, is a synthetic estrogen which is used topically in a 1% cream formulation for the treatment of vaginal atrophy in women. It is the 3-propyl and 17β-methyl diether of estradiol and does not appear to convert into estradiol in the body. Promestriene is minimally absorbed and appears to have negligible systemic estrogenic effect. The drug has been described as a tropic agent and antiseborrheic. It has not been found to be effective in the treatment of pattern hair loss or other conditions of cutaneous androgenization. Promestriene was first introduced in France in 1974 and has been marketed in 34 countries worldwide. It has been used in millions of women. — Wikipedia
Clinical trial activity
8 trials · 12 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2010 (NCT01153958)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Estrogen receptorAGONIST
Estrogen receptor agonist
Chemistry & pharmacology
SMILES
CCCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](OC)CC[C@@H]12- Mol. weight
- 328.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPromestriene ↗
- ChEMBLCHEMBL2105394 ↗
Also known as
- 17 beta-methoxy-3-propoxyestra-1,3,5(10)-triene
- 3-propoxy-17 beta-methoxy-1,3,5(10)-estratriene
- colpotrofin
- colpotrophine
- delipoderm
- grunenthal brand of promestriene
- promestriene
- promestriene
- promestriene
- promestriene
- promestriene
- promestriene
- promestriene
- promestriene
- reig jofre brand of promestriene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07153276 | Phase 4 | Jan 19, 2026 | Fundação de Amparo à Pesquisa do Estado de São Paulo, University of Sao Paulo |
| NCT04657536 | N/A | Dec 31, 2020 | Chinese Association of Plastics and Aesthetics, Peking University |
| NCT04232813 | Phase 3 | Jan 9, 2020 | Instituto Palacios, Novo Nordisk |
| NCT04081805 | N/A | Sep 30, 2019 | Federal University of Sao Paulo, Fundação de Amparo à Pesquisa do Estado de São Paulo |
| NCT04717245 | N/A | Oct 25, 2018 | University of Sao Paulo |
| NCT03032848 | Phase 4 | Nov 26, 2013 | Universidade Federal do Parana |
| NCT01370798 | Phase 3 | May 1, 2011 | Hopital Femme Mere Enfant, University of Lyon |
| NCT01153958 | Phase 4 | Jul 1, 2010 | Merck KGaA, Merck Serono |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Academic/Hospital | 2 | 0 | 2 | 2019 |
| University of Sao Paulo | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Chinese Association of Plastics and Aesthetics | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Federal University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Hopital Femme Mere Enfant | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Instituto Palacios | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2010 |
| Merck Serono | For profit | 1 | 0 | 1 | 2010 |
| Novo Nordisk | For profit | 1 | 0 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Universidade Federal do Parana | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2011 |